|
US5612359A
(en)
|
1994-08-26 |
1997-03-18 |
Bristol-Myers Squibb Company |
Substituted biphenyl isoxazole sulfonamides
|
|
CN1072649C
(zh)
|
1995-09-13 |
2001-10-10 |
武田药品工业株式会社 |
苯并氧杂吖庚因化合物,其生产方法和用途
|
|
TW536540B
(en)
|
1997-01-30 |
2003-06-11 |
Bristol Myers Squibb Co |
Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
|
|
US6628343B1
(en)
|
1997-05-23 |
2003-09-30 |
Sony Corporation |
Television signal reception circuit, automatic phase shift control circuit and equal amplitude addition circuit
|
|
ID26984A
(id)
|
1998-07-06 |
2001-02-22 |
Bristol Myers Squibb Co |
Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
AR035016A1
(es)
|
1999-08-25 |
2004-04-14 |
Takeda Chemical Industries Ltd |
Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
|
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
|
EP1302462A4
(en)
|
2000-07-17 |
2007-07-18 |
Takeda Pharmaceutical |
SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
|
|
WO2003072197A1
(en)
|
2002-02-27 |
2003-09-04 |
Pfizer Products Inc. |
Acc inhibitors
|
|
BR0315815A
(pt)
|
2002-11-01 |
2005-09-13 |
Takeda Pharmaceutical |
Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
|
|
AU2003277576A1
(en)
|
2002-11-08 |
2004-06-07 |
Takeda Pharmaceutical Company Limited |
Receptor function controlling agent
|
|
US20070004736A1
(en)
|
2002-11-22 |
2007-01-04 |
Keiji Kubo |
Imidazole derivative, process for producing the same, and use
|
|
US7820837B2
(en)
|
2003-05-30 |
2010-10-26 |
Takeda Pharmaceutical Company Limited |
Condensed ring compound
|
|
EP1669352A4
(en)
|
2003-09-30 |
2008-12-17 |
Takeda Pharmaceutical |
THIAZOLINE DERIVATIVE AND ITS USE
|
|
WO2005058823A1
(ja)
|
2003-12-17 |
2005-06-30 |
Takeda Pharmaceutical Company Limited |
ウレア誘導体、その製造法及び用途
|
|
JP2007537141A
(ja)
|
2003-12-18 |
2007-12-20 |
ノボ ノルディスク アクティーゼルスカブ |
新規なglp−1化合物
|
|
US7456218B2
(en)
|
2003-12-25 |
2008-11-25 |
Takeda Pharmaceutical Company Limited |
3-(4-benzyloxyphenyl) propanoic acid derivatives
|
|
WO2005063725A1
(ja)
|
2003-12-26 |
2005-07-14 |
Takeda Pharmaceutical Company Limited |
フェニルプロパン酸誘導体
|
|
WO2005087710A1
(ja)
|
2004-03-15 |
2005-09-22 |
Takeda Pharmaceutical Company Limited |
アミノフェニルプロパン酸誘導体
|
|
JP4859665B2
(ja)
|
2004-03-30 |
2012-01-25 |
武田薬品工業株式会社 |
アルコキシフェニルプロパン酸誘導体
|
|
TWI396686B
(zh)
|
2004-05-21 |
2013-05-21 |
Takeda Pharmaceutical |
環狀醯胺衍生物、以及其製品和用法
|
|
GEP20094723B
(en)
|
2004-05-25 |
2009-07-10 |
Pfizer Prod Inc |
Tetraazabenzo [e] azulene derivatives and analogs thereof
|
|
US20050287100A1
(en)
|
2004-06-08 |
2005-12-29 |
Lebre Caroline |
Cosmetic composition comprising a semi-crystalline polymer and a dispersion of polymer in fatty phase
|
|
US20060275288A1
(en)
|
2005-01-20 |
2006-12-07 |
Grihalde Nelson D |
GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
|
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
US8957070B2
(en)
|
2005-04-20 |
2015-02-17 |
Takeda Pharmaceutical Company Limited |
Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
|
|
EP1916234B1
(en)
|
2005-07-29 |
2014-11-12 |
Takeda Pharmaceutical Company Limited |
Cyclopropanecarboxylic acid compound
|
|
US20090054435A1
(en)
|
2005-07-29 |
2009-02-26 |
Hiroshi Imoto |
Phenoxyalkanoic Acid Compound
|
|
JP4094660B1
(ja)
|
2005-08-10 |
2008-06-04 |
武田薬品工業株式会社 |
糖尿病治療剤
|
|
JP2007063225A
(ja)
|
2005-09-01 |
2007-03-15 |
Takeda Chem Ind Ltd |
イミダゾピリジン化合物
|
|
EP2010520B1
(en)
|
2006-04-20 |
2012-09-12 |
Pfizer Products Inc. |
Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
|
|
AU2007265966B2
(en)
|
2006-06-27 |
2012-05-17 |
Takeda Pharmaceutical Company Limited |
Fused cyclic compounds
|
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
EP2298772A1
(en)
|
2006-10-18 |
2011-03-23 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compounds
|
|
CN101573357B
(zh)
|
2006-10-19 |
2013-01-23 |
武田药品工业株式会社 |
吲哚化合物
|
|
WO2008065508A1
(en)
|
2006-11-29 |
2008-06-05 |
Pfizer Products Inc. |
Spiroketone acetyl-coa carboxylase inhibitors
|
|
WO2008093639A1
(ja)
|
2007-01-29 |
2008-08-07 |
Takeda Pharmaceutical Company Limited |
ピラゾール化合物
|
|
AU2008215490A1
(en)
|
2007-02-09 |
2008-08-21 |
Takeda Pharmaceutical Company Limited |
Fused ring compounds as partial agonists of PPAR-gamma
|
|
JPWO2008136428A1
(ja)
|
2007-04-27 |
2010-07-29 |
武田薬品工業株式会社 |
含窒素5員複素環化合物
|
|
EP2157859A4
(en)
|
2007-06-19 |
2011-01-12 |
Takeda Pharmaceutical |
INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
|
|
JP5435592B2
(ja)
|
2008-05-28 |
2014-03-05 |
ファイザー・インク |
ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
|
|
EP2297164A1
(en)
|
2008-05-28 |
2011-03-23 |
Pfizer Inc. |
Pyrazolospiroketone acetyl-coa carboxylase inhibitors
|
|
ES2558842T3
(es)
|
2008-06-17 |
2016-02-09 |
Indiana University Research And Technology Corporation |
Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
|
|
CA2729581A1
(en)
|
2008-07-29 |
2010-02-04 |
Pfizer Inc. |
Fluorinated heteroaryls
|
|
ES2380408T3
(es)
|
2008-08-28 |
2012-05-11 |
Pfizer Inc. |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
|
|
TW201038580A
(en)
|
2009-02-02 |
2010-11-01 |
Pfizer |
4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
|
|
EP2406230A1
(en)
|
2009-03-11 |
2012-01-18 |
Pfizer Inc. |
Substituted indazole amides and their use as glucokinase activators
|
|
WO2010103437A1
(en)
|
2009-03-11 |
2010-09-16 |
Pfizer Inc. |
Benzofuranyl derivatives used as glucokinase inhibitors
|
|
CA2754523A1
(en)
|
2009-03-20 |
2010-09-23 |
Pfizer Inc. |
3-oxa-7-azabicyclo[3.3.1]nonanes
|
|
EP2427448A1
(en)
|
2009-05-08 |
2012-03-14 |
Pfizer Inc. |
Gpr 119 modulators
|
|
CA2759843A1
(en)
|
2009-05-08 |
2010-11-10 |
Pfizer Inc. |
Gpr 119 modulators
|
|
GEP20135907B
(en)
|
2009-06-05 |
2013-08-12 |
Pfizer |
L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
US20120021979A1
(en)
|
2010-06-24 |
2012-01-26 |
Vanderbilt University |
GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
|
|
DK2621493T3
(en)
|
2010-09-30 |
2016-10-24 |
Pfizer |
N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
|
|
JP6126097B2
(ja)
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー/エス |
Glp−1誘導体
|
|
JP6573604B2
(ja)
|
2013-06-11 |
2019-09-11 |
セルジーン インターナショナル ツー エスエーアールエル |
新規なglp−1レセプターモジュレーター
|
|
CN107074820B
(zh)
|
2014-07-25 |
2021-05-18 |
赛尔基因第二国际有限公司 |
Glp-1受体调节剂
|
|
JP6712323B2
(ja)
|
2015-12-31 |
2020-06-17 |
ハンミ ファーマシューティカル カンパニー リミテッド |
グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
WO2018109607A1
(en)
*
|
2016-12-16 |
2018-06-21 |
Pfizer Inc. |
Glp-1 receptor agonists and uses thereof
|
|
JP7161605B2
(ja)
|
2018-08-31 |
2022-10-26 |
ファイザー・インク |
Nash/nafldおよび関連疾患の治療のための組合せ
|
|
EA202191432A1
(ru)
*
|
2018-11-22 |
2021-10-14 |
Цилу Регор Терапьютикс Инк. |
Агонисты glp-1r и их применения
|
|
EP3890748A4
(en)
|
2018-12-05 |
2022-12-21 |
Viking Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
|
|
CA3140972C
(en)
|
2019-05-20 |
2024-06-18 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
PT4097099T
(pt)
|
2020-02-07 |
2024-07-19 |
Gasherbrum Bio Inc |
Agonistas heterocíclicos de glp-1
|